-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $239

Benzinga·08/27/2026 13:02:25
Listen to the news
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $231 to $239.